Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Escapes COVID Impact With 2% Underlying Growth

R&D Spend To Rise 15%

Executive Summary

Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market. 

You may also be interested in...



APAC Life Sciences Valuation Trends: Chinese Firms Eclipse Japan, India Peers

Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.

Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business

In a widely anticipated move, Takeda has confirmed the sale of its consumer healthcare business in Japan, to the US private equity group Blackstone.

Coronavirus Update: Sotrovimab Filed For EUA In Japan

GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC144341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel